Compare IFN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFN | ARVN |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.6M | 516.2M |
| IPO Year | 1994 | 2018 |
| Metric | IFN | ARVN |
|---|---|---|
| Price | $11.47 | $9.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $15.05 |
| AVG Volume (30 Days) | 124.8K | ★ 898.7K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.51 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.72 | $6.97 |
| 52 Week High | $15.47 | $14.22 |
| Indicator | IFN | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 58.81 |
| Support Level | $11.40 | $7.90 |
| Resistance Level | $11.79 | $9.65 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 2.91 | 73.65 |
India Fund Inc is a non-diversified closed-end management investment company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.